Can Janssen Revive Its Key Remicade Patent? Federal Circuit Hears Pitch
Oral arguments suggest Janssen may have difficulty getting reversal of district court and patent office rulings that its composition patent is invalid.
You may also be interested in...
Pfizer v. J&J Sets Stage For Biosimilar Showdown Over Exclusive Contracts
Pfizer's suit claims J&J coerced payers by vowing to withhold all Remicade rebates if any of Pfizer's biosimilar Inflectra is reimbursed, but J&J says Pfizer has failed to show the value of Inflectra.
Merck's Second-To-Market Renflexis Biosimilar Priced Below The First
Merck & Co. launched Renflexis in the US, marking the first time two biosimilars will compete for share against a brand, in this case J&J's Remicade.
Remicade: Biosimilars And Pricing Pressure Wear On J&J's Blockbuster Brand
US sales were down 14%, but much of the hit was due to a 2016 price adjustment that was felt across the pharma portfolio, and execs insisted the impact of biosimilars is more moderate than expected.